Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
Tainan City, TW
Primarily based in Taiwan, Nang Kuang Pharmaceutical Co., Ltd. functions as a pharmaceutical enterprise. Its comprehensive product range includes various sterile injectable forms such as parenterals, aseptic parenterals, lyophilized injections, pre-filled syringes, and pre-mixed intravenous (IV) infusion bags. Additionally, it manufactures conventional dosage forms like tablets, capsules, oral suspensions, and topical applications. The company's offerings span a wide array of therapeutic categories, including treatments for cardiovascular, gastrointestinal, and nervous system disorders; alimentary and metabolic conditions; blood-related issues; antineoplastic and immunomodulatory agents; musculoskeletal and respiratory ailments; dermatological concerns; genito-urinary and sex hormone therapies; systemic hormones; and systemic antibacterials. Nang Kuang also supplies cosmetic products and comprehensive hospital solutions. Furthermore, Nang Kuang specializes in advanced pharmaceutical technologies, producing sterile and anticancer injectable products, controlled-release formulations (both injectable and oral), and oral disintegrating tablets. Founded in 1963, Nang Kuang Pharmaceutical Co., Ltd. is headquartered in Tainan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.22% | -4.42% | -8.86% | -12.90% | -15.73% | -13.14% | -13.02% | -53.18% | -16.82% | -16.82% | -16.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-1.7% Q1'26: -8.6% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+0.8% Q1'26: -54.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+11.0% Q1'26: +23.9% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+13.7% ★ Q1'26: +13.4% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+8.9% ★ Q1'26: +7.2% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.4% ★ Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.37× Q1'26: 2.32× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.52B
est: 1.52B (+0.0%)
|
1.55B
est: 1.56B (-0.6%)
|
1.50B
est: 1.56B (-3.5%)
|
1.54B
est: 1.56B (-1.2%)
|
1.76B
est: 1.72B (+2.3%)
|
1.75B
est: 1.76B (0.0%)
|
1.78B
est: 1.79B (-0.6%)
|
1.94B
est: 1.90B (+2.1%)
|
2.15B
est: 2.20B (-2.4%)
|
2.20B
est: 2.19B (+0.3%)
|
2.16B
est: 2.30B (-6.1%)
|
| EBITDA |
378.00M
est: 360.48M (+4.9%)
|
447.71M
est: 369.71M (+21.1%)
|
339.54M
est: 369.71M (-8.2%)
|
318.31M
est: 369.11M (-13.8%)
|
447.01M
est: 408.60M (+9.4%)
|
412.99M
est: 416.19M (-0.8%)
|
417.83M
est: 424.49M (-1.6%)
|
591.57M
est: 450.81M (+31.2%)
|
402.70M
est: 522.31M (-22.9%)
|
491.69M
est: 513.96M (-4.3%)
|
478.81M
est: 539.50M (-11.3%)
|
| EBIT |
211.01M
est: 219.15M (-3.7%)
|
276.15M
est: 224.76M (+22.9%)
|
161.02M
est: 224.76M (-28.4%)
|
122.23M
est: 224.40M (-45.5%)
|
254.30M
est: 248.40M (+2.4%)
|
227.92M
est: 253.02M (-9.9%)
|
238.29M
est: 258.06M (-7.7%)
|
415.46M
est: 274.07M (+51.6%)
|
220.86M
est: 317.53M (-30.4%)
|
308.73M
est: 319.20M (-3.3%)
|
295.67M
est: 335.06M (-11.8%)
|
| Net Income |
198.99M
est: 216.35M (-8.0%)
|
225.50M
est: 197.45M (+14.2%)
|
185.82M
est: 189.01M (-1.7%)
|
101.23M
est: 115.94M (-12.7%)
|
217.44M
est: 195.42M (+11.3%)
|
183.40M
est: 182.26M (+0.6%)
|
196.11M
est: 193.90M (+1.1%)
|
352.00M
est: 267.31M (+31.7%)
|
198.41M
est: 308.82M (-35.8%)
|
243.41M
est: 213.71M (+13.9%)
|
243.95M
est: 236.89M (+3.0%)
|
| SGA |
232.04M
est: 180.32M (+28.7%)
|
229.53M
est: 184.93M (+24.1%)
|
219.49M
est: 184.93M (+18.7%)
|
217.20M
est: 184.64M (+17.6%)
|
243.56M
est: 204.39M (+19.2%)
|
211.74M
est: 208.18M (+1.7%)
|
204.05M
est: 212.34M (-3.9%)
|
227.29M
est: 225.50M (+0.8%)
|
252.78M
est: 261.27M (-3.2%)
|
270.88M
est: 262.44M (+3.2%)
|
272.24M
est: 275.49M (-1.2%)
|
| EPS |
2.17
est: 2.14 (+1.6%)
|
2.25
est: 1.95 (+15.4%)
|
1.84
est: 1.87 (-1.4%)
|
1.00
est: 1.15 (-12.7%)
|
2.17
est: 1.93 (+12.4%)
|
1.82
est: 1.80 (+1.1%)
|
1.94
est: 1.92 (+1.3%)
|
3.49
est: 2.64 (+32.2%)
|
1.96
est: 3.05 (-35.7%)
|
2.41
est: 2.12 (+13.7%)
|
2.42
est: 2.35 (+3.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 25.0K | 0.46% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 990.53 | 0.42% |
| 3 | Avantis Emerging Markets Value ETF AVES | 0.00% | 10.9K | 0.36% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 59.0K | 0.39% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 37.9K | 0.29% |
| 6 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 66.0K | 0.33% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 25.9K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hsiu-Mei Chao | Accounting Officer & Chief Internal Auditor | — | — |
| Ling-Jun Tu | Chief Financial Officer | — | — |
| Lizhen Lai | Accounting Supervisor | — | — |
| Yu-Bei Wang | General Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1752.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
